Tharimmune Corp (THAR) Total Debt to Capital

The current price chart for Tharimmune, Inc. (THAR) allows for an assessment of the biotech's debt load, where management effectively attracts venture capital in the absence of recurring revenue. Tharimmune, Inc. (THAR) integrates immunotherapy development with the blockchain finances of the Canton network, and its indicator stands at 0.03. The business is currently focusing on deploying phase II trials of targeted antibodies to combat oncology symptoms.

To identify fundamental leaders in biopharmaceuticals, the analyst evaluates the financing structure through total liabilities relative to equity. This metric determines the business's degree of dependence on borrowed funds, which is critical for Tharimmune, Inc. (THAR) when implementing costly immunotherapy developments; therefore, the company's debt-to-equity ratio on this chart serves as an indicator of the balance between expansion and financial stability.